In the original article, there was a mistake in Figure 7C as published. By error, the image for FAS-L treated with MMF was included twice; once correctly and once as FAS-L treated with vehicle control. The corrected Figure 7C for FAS-L assessments appears below.
Figure 7
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
fingolimod, dimethyl fumarate, Gilenya, Tecfidera, RAS, glioblastoma, microglia
Citation
Dent P, Booth L, Roberts JL, Poklepovic A and Hancock JF (2020) Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells. Front. Oncol. 10:684. doi: 10.3389/fonc.2020.00684
Received
11 March 2020
Accepted
14 April 2020
Published
30 April 2020
Volume
10 - 2020
Edited and reviewed by
Liam Chen, Johns Hopkins University, United States
Updates
Copyright
© 2020 Dent, Booth, Roberts, Poklepovic and Hancock.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Paul Dent paul.dent@vcuhealth.orgLaurence Booth laurence.booth@vcuhealth.org
This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.